Latin America’s Drug Delivery Market to Reach €87 Billion by 2031

Latin America’s healthcare sector is undergoing a profound transformation. While pharmaceutical innovation has traditionally focused on developing new medicines, the next wave of growth is increasingly centered on how those treatments are delivered to patients.

According to a new report by MarketsandMarkets, the Latin American pharmaceutical drug delivery market is expected to grow from approximately €64 billion in 2026 to nearly €87 billion by 2031, representing a compound annual growth rate (CAGR) of 6.3%. The market was valued at around €61.8 billion in 2025, highlighting sustained expansion driven by demographic, technological and healthcare trends.

The report points to a structural shift across Latin America’s healthcare systems, where providers are adopting technologies that improve treatment adherence, facilitate self-administration and reduce pressure on hospitals by enabling more patients to receive care at home.

Countries including Brazil, Mexico, Argentina and Colombia are leading this transition as governments and healthcare providers invest in more efficient treatment models capable of responding to the growing burden of chronic diseases.

Chronic diseases accelerate demand for advanced therapies

The rise in cancer, diabetes, cardiovascular conditions and autoimmune diseases is fueling demand for more sophisticated drug delivery systems capable of improving both clinical outcomes and patient experience.

Manufacturers are increasingly developing prefilled syringes, autoinjectors, wearable injectors, inhalers, transdermal patches and long-acting injectable therapies, technologies designed to simplify treatment while reducing hospital visits and improving adherence.

These innovations are becoming essential as healthcare systems seek to combine better patient outcomes with greater operational efficiency.

A strategic opportunity for European pharmaceutical companies

The report identifies several leading European pharmaceutical groups among the companies best positioned to benefit from this market expansion, including Roche, Novartis, Sanofi, AstraZeneca, Bayer and GSK.

Europe’s leadership in biologics, oncology, vaccines and advanced medical technologies places its pharmaceutical industry in a strong position to capture growing demand throughout Latin America.

At the same time, regulators across the region—including Brazil’s ANVISA, Mexico’s COFEPRIS, Argentina’s ANMAT and Colombia’s INVIMA—continue strengthening regulatory frameworks governing combination drug-device products, manufacturing standards and patient safety, creating a more attractive environment for international investment.

Home healthcare becomes a major growth driver

One of the report’s most significant findings is the growing shift from hospital-based care toward home treatment.

Healthcare providers are increasingly encouraging patients to administer therapies outside clinical settings through connected devices and smart delivery technologies that improve convenience while reducing costs.

Injectable drug delivery systems currently dominate the regional market, supported by expanding use of biologic medicines and biosimilars. Meanwhile, treatments for autoimmune diseases are expected to register the fastest growth through 2031.

The evolution reflects a broader transformation taking place across global healthcare, where digital monitoring, personalized medicine and patient-centered care are becoming central pillars of pharmaceutical innovation.

Europe and Latin America deepen healthcare cooperation

For Europe, Latin America’s expanding pharmaceutical market represents more than a commercial opportunity.

European companies continue to strengthen their presence across the region through manufacturing investments, technology transfer, research partnerships and commercialization agreements, reinforcing healthcare cooperation between both regions.

Industry analysts believe the market’s expansion will also benefit companies operating in medical devices, pharmaceutical packaging, biotechnology, digital health and connected healthcare technologies.

As healthcare systems modernize, demand is expected to extend well beyond pharmaceutical products to include integrated solutions capable of improving treatment efficiency throughout the patient journey.

Drug delivery emerges as the next frontier of pharmaceutical innovation

The report highlights an important shift within the global pharmaceutical industry.

Competitive advantage will increasingly depend not only on discovering new therapies but also on developing safer, smarter and more effective ways of delivering them.

For Latin America, this evolution offers an opportunity to modernize healthcare systems, expand access to advanced treatments and improve long-term patient outcomes.

For Europe, it reinforces the region’s role as a strategic technology and investment partner at a time when healthcare innovation is becoming one of the world’s fastest-growing industries.

With the market expected to approach €87 billion by 2031, pharmaceutical drug delivery is emerging as one of the most attractive healthcare investment opportunities connecting Europe and Latin America over the coming decade.